GlycoMimetics To Host Leader Event To Review Results From Pivotal Phase 3 Study Of Uproleselan In Relapsed/Refractory Acute Myeloid Leukemia On June 4, 2024
GlycoMimetics To Host Leader Event To Review Results From Pivotal Phase 3 Study Of Uproleselan In Relapsed/Refractory Acute Myeloid Leukemia On June 4, 2024
GlycoMimetics, Inc. (NASDAQ:GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it will host a key opinion leader event on Tuesday, June 4, 2024, at 8:30am ET to provide a comprehensive overview of data from the company's pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML).
GlycoMimetics公司（納斯達克股票代碼：GLYC）是一家後期臨床階段的生物技術公司，發現和開發基於糖生物學的癌症和炎症疾病治療方案。今天宣佈，該公司將於2024年6月4日星期二上午8:30美國東部時間舉行主題演講活動，全面介紹公司在復發/難治（R/R）急性髓系白血病（AML）中使用uproleselan的關鍵階段3研究的數據。
The event will feature the study's principal investigator Daniel DeAngelo, M.D., Ph.D., Professor of Medicine, Harvard Medical School, and Chief of the Division of Leukemia, Dana-Farber Cancer Institute, who will discuss results from the pivotal Phase 3 study of uproleselan, along with the current AML treatment landscape and unmet patient need.
這次演講將由本研究的首席調查員、哈佛醫學院醫學教授、白血病科主任（Dana-Farber Cancer Institute）Daniel DeAngelo萬.D.博士主講，討論關鍵階段3研究uproleselan的結果，以及當前AML治療領域的短板和需要改進之處。
To access the event by phone, please go to this registration link to obtain the dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time.
如需通過電話參加本次活動，請前往註冊鏈接以獲取撥入詳情。建議參與者提前15分鐘連接。
A live webcast of the call will be available on the "Investors" tab on the GlycoMimetics website. A webcast replay will be available for 30 days following the call.
本次通話的直播將在GlycoMimetics網站的“投資者”選項卡上提供。通話重播將在通話後30天內提供。